GSK5764227 + dostarlimab

GSK5764227 + dostarlimab is an investigational **combination therapy** comprising GSK5764227, a B7-H3-targeted antibody-drug conjugate, and dostarlimab, a PD-1 inhibitor monoclonal antibody. GSK5764227 is designed to deliver a topoisomerase I inhibitor payload specifically to tumor cells overexpressing B7-H3, leading to targeted cytotoxicity, while dostarlimab enhances immune response by blocking the PD-1 pathway, facilitating T-cell mediated antitumor activity. GSK5764227 is under development for multiple solid tumor types, including osteosarcoma, small cell lung cancer, and gastrointestinal cancers, with studies sponsored by GSK and Hansoh Pharma. Dostarlimab is approved for certain gynecologic cancers and is developed by GSK.

Other names

GSK5764227 + dostarlimab